Trader J's Inner Circle Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle

NVDA 186.96

-3.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (7421)	2/3/1999 9:19:00 AM
From: Mike McFarland	Read Replies (1) of 56532

re Incyte...earnings For the quarter ended December 31, 1998, Incyte reported revenues of $36.6 million resulting in net income of $1.5 million or $0.05 per diluted share... The net income for the quarter and year ended December 31, 1998 were impacted by the ramp up in expenses related to the genomic sequencing and single nucleotide polymorphism (SNP) discovery programs previously attributed to the Incyte Genetics business unit. Excluding the impact of this business unit, net income would have been $6.9 million or diluted earnings per share of $0.23 for the quarter ended December 31, 1998. --and it looks like they are not going to do the tracking stock...Incyte Genetics, so perhaps the earnings estimates were already excluding that? biz.yahoo.com So I am pretty sure that earnings were forecast as .77/.21 and turned out .54/.05, but we have to consider that they may actually have been in line based in whether the Incyte Genetics unit was supposed to be in there.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next